Variant Bio Inc.

Based in the US, Variant Bio Inc. specializes in developing life-saving therapies by leveraging human genetics to analyze genes from individuals with exceptional health traits, thereby improving clinical trial success rates. Variant Bio Inc. focuses on developing therapies informed by human genetics.

Founded in 2018 in New York, US, it has undergone three significant deals. The latest round of funding was USD 50. 00 mn from Novo Nordisk on January 7, 2025, bringing the total raised to USD 50. 00 mn.

The founders include Kaja Wasik and Stephane Castel, while Andrew Farnum serves as CEO. Variant Bio's primary focus is on developing life-saving therapies through the study of human genetics, particularly by analyzing genes from individuals exhibiting exceptional health-related traits. By leveraging insights from human genetics, the company aims to identify the molecular basis of diseases, thereby improving the success rates of clinical trials significantly. The firm operates at the intersection of genetics, drug discovery, molecular biology, anthropology, and ethics, ensuring a comprehensive approach to drug development.

Their collaborative model involves partnering with diverse communities globally, demonstrating a commitment to ethical research practices while benefiting those communities involved. Variant Bio's services address critical healthcare challenges in North America, Europe, and specific regions in Africa and Oceania, targeting healthcare providers, pharmaceutical companies, and research institutions. Variant Bio's revenue structure is predicated on partnerships and collaborations in the biotechnology and pharmaceutical sectors. The company engages in B2B transactions, primarily collaborating with academic institutions and healthcare providers to facilitate genomic research initiatives and therapeutic development.

Revenue is generated through a combination of research grants, partnership agreements, and milestone payments associated with successful clinical advancements of their therapeutic candidates. While specific pricing plans for their services are not disclosed, transactions typically involve contractual frameworks where funding is provided based on project milestones and deliverables, aligning with the objectives of their partners. The focus on ethically-grounded research not only underpins their revenue model but also strengthens their relationships with client communities, ensuring mutual benefit and shared success. In January 2025, Variant Bio Inc.

raised USD 50 mn in venture funding from new investor Novo Nordisk to support disease research and development. The company is actively working on the design and launch of new therapeutic products, with specific release dates to be determined. Additionally, Variant Bio plans to expand its reach into emerging markets in Africa and Oceania by the end of 2025, leveraging the recent funding to enhance their research capabilities and build partnerships in these regions.